Citation Impact
Citing Papers
Loss of 53BP1 Causes PARP Inhibitor Resistance in Brca1 -Mutated Mouse Mammary Tumors
2012
A Marker of Homologous Recombination Predicts Pathologic Complete Response to Neoadjuvant Chemotherapy in Primary Breast Cancer
2010
PTEN Loss Compromises Homologous Recombination Repair in Astrocytes: Implications for Glioblastoma Therapy with Temozolomide or Poly(ADP-Ribose) Polymerase Inhibitors
2010
Functional Restoration of BRCA2 Protein by Secondary BRCA2 Mutations in BRCA2 -Mutated Ovarian Carcinoma
2009
Stereospecific PARP Trapping by BMN 673 and Comparison with Olaparib and Rucaparib
2013
Development of a Functional Assay for Homologous Recombination Status in Primary Cultures of Epithelial Ovarian Tumor and Correlation with Sensitivity to Poly(ADP-Ribose) Polymerase Inhibitors
2010
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
Poly(ADP)-Ribose Polymerase Inhibition: Frequent Durable Responses in BRCA Carrier Ovarian Cancer Correlating With Platinum-Free Interval
2010
BRCA1-Associated Epigenetic Regulation of p73 Mediates an Effector Pathway for Chemosensitivity in Ovarian Carcinoma
2010
Vulnerabilities of PTEN – TP53 -Deficient Prostate Cancers to Compound PARP–PI3K Inhibition
2014
Sulfur [ 18 F]Fluoride Exchange Click Chemistry Enabled Ultrafast Late-Stage Radiosynthesis
2021 StandoutNobel
BMN 673, a Novel and Highly Potent PARP1/2 Inhibitor for the Treatment of Human Cancers with DNA Repair Deficiency
2013
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Triple negative breast cancer: unmet medical needs
2010
Comprehensive molecular portraits of human breast tumours
2012 StandoutNature
Olaparib in patients with recurrent high-grade serous or poorly differentiated ovarian carcinoma or triple-negative breast cancer: a phase 2, multicentre, open-label, non-randomised study
2011
Hallmarks of Cancer: The Next Generation
2011 Standout
Triple-Negative Breast Cancer
2010 Standout
The DNA-damage response in human biology and disease
2009 StandoutNature
The contribution of gene expression profiling to breast cancer classification, prognostication and prediction: a retrospective of the last decade
2009
A view on drug resistance in cancer
2019 StandoutNature
The ATM–Chk2 and ATR–Chk1 Pathways in DNA Damage Signaling and Cancer
2010
BRCAness revisited
2016
Cell cycle proteins as promising targets in cancer therapy
2017 Standout
PARP inhibitor combination therapy
2016
Olaparib: First Global Approval
2015
Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future
2017 Standout
Tumor heterogeneity: Causes and consequences
2009
Genetic Interactions in Cancer Progression and Treatment
2011
Cancer drug resistance: an evolving paradigm
2013 Standout
Hallmarks of aging: An expanding universe
2023 Standout
Unravelling the complexity of metastasis — molecular understanding and targeted therapies
2011
Shaping human telomeres: from shelterin and CST complexes to telomeric chromatin organization
2021 Nobel
Network pharmacology: the next paradigm in drug discovery
2008 Standout
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
2016 Standout
The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance
2012
CRISPR-Cas9 Circular Permutants as Programmable Scaffolds for Genome Modification
2019 StandoutNobel
The mini-driver model of polygenic cancer evolution
2015 StandoutNobel
Analysis of Circulating Tumor DNA to Monitor Metastatic Breast Cancer
2013 Standout
The multilayered complexity of ceRNA crosstalk and competition
2014 StandoutNature
The PARP Side of the Nucleus: Molecular Actions, Physiological Outcomes, and Clinical Targets
2010
Structural Basis of Detection and Signaling of DNA Single-Strand Breaks by Human PARP-1
2015
Structural Basis and Sequence Rules for Substrate Recognition by Tankyrase Explain the Basis for Cherubism Disease
2011
Molecular mechanisms of cisplatin resistance
2011 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and recurrent ovarian cancer: a proof-of-concept trial
2010 Standout
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Repair of Strand Breaks by Homologous Recombination
2013
Hypoxia-inducible factor–dependent breast cancer–mesenchymal stem cell bidirectional signaling promotes metastasis
2012 StandoutNobel
DNA Damage, Aging, and Cancer
2009 Standout
Structures of Human Exonuclease 1 DNA Complexes Suggest a Unified Mechanism for Nuclease Family
2011 StandoutNobel
Breast cancer genomes — form and function
2010
Intra-tumour heterogeneity: a looking glass for cancer?
2012
Mitotic homologous recombination maintains genomic stability and suppresses tumorigenesis
2010
MMEJ repair of double-strand breaks (director’s cut): deleted sequences and alternative endings
2008
Tumour heterogeneity and cancer cell plasticity
2013 StandoutNature
Mechanisms of resistance to therapies targeting BRCA-mutant cancers
2013
Emerging Biological Principles of Metastasis
2017 Standout
The DNA damage response and cancer therapy
2012 Nature
NLK Is a Novel Therapeutic Target for PTEN Deficient Tumour Cells
2012
The causes and consequences of genetic heterogeneity in cancer evolution
2013 StandoutNature
One-Step Generation of Mice Carrying Mutations in Multiple Genes by CRISPR/Cas-Mediated Genome Engineering
2013 Standout
Applications of CRISPR technologies in research and beyond
2016 StandoutNobel
Synthetic lethality: the road to novel therapies for breast cancer
2016
Alternative-NHEJ Is a Mechanistically Distinct Pathway of Mammalian Chromosome Break Repair
2008
Therapeutic potential of PARP inhibitors for metastatic breast cancer
2011
The role of tandem duplicator phenotype in tumour evolution in high‐grade serous ovarian cancer
2011
Olaparib Maintenance Therapy in Platinum-Sensitive Relapsed Ovarian Cancer
2012 Standout
Synthetic lethal therapies for cancer: what’s next after PARP inhibitors?
2018
Clonal evolution in cancer
2012 StandoutNature
The functions and regulation of the PTEN tumour suppressor
2012 Standout
The Hallmarks of Aging
2013 Standout
The PI3K Pathway in Human Disease
2017 Standout
Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial
2010 Standout
Metastatic colonization by circulating tumour cells
2016 StandoutNature
Inhibition of Poly(ADP-Ribose) Polymerase in Tumors from BRCA Mutation Carriers
2009 Standout
Integrative molecular profiling of triple negative breast cancers identifies amplicon drivers and potential therapeutic targets
2010
Synthetic lethality: General principles, utility and detection using genetic screens in human cells
2010
Proteome-wide Profiling of Clinical PARP Inhibitors Reveals Compound-Specific Secondary Targets
2016
Emerging targeted agents in metastatic breast cancer
2013
Synthetic Lethal Interaction between Oncogenic KRAS Dependency and STK33 Suppression in Human Cancer Cells
2009
Cancer genomics: from discovery science to personalized medicine
2011
Circadian clock disruption improves the efficacy of chemotherapy through p73-mediated apoptosis
2011 StandoutNobel
Effective use of PI3K inhibitor BKM120 and PARP inhibitor Olaparib to treat PIK3CA mutant ovarian cancer
2016
Secondary Somatic Mutations RestoringBRCA1/2Predict Chemotherapy Resistance in Hereditary Ovarian Carcinomas
2011
Mechanisms of double-strand break repair in somatic mammalian cells
2009
Nonhomologous end joining drives poly(ADP-ribose) polymerase (PARP) inhibitor lethality in homologous recombination-deficient cells
2011
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Laying a trap to kill cancer cells: PARP inhibitors and their mechanisms of action
2016
Secondary mutations in BRCA2 associated with clinical resistance to a PARP inhibitor
2012
Noninvasive Identification and Monitoring of Cancer Mutations by Targeted Deep Sequencing of Plasma DNA
2012
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Gene Expression Profile of BRCAness That Correlates With Responsiveness to Chemotherapy and With Outcome in Patients With Epithelial Ovarian Cancer
2010
Hunting Viral Receptors Using Haploid Cells
2015
Classification of Intrinsically Disordered Regions and Proteins
2014 Standout
High sensitivity of BRCA1-deficient mammary tumors to the PARP inhibitor AZD2281 alone and in combination with platinum drugs
2008
A Synthetic Lethal Therapeutic Approach: Poly(ADP) Ribose Polymerase Inhibitors for the Treatment of Cancers Deficient in DNA Double-Strand Break Repair
2008
Functional genomics of lipid metabolism in the oleaginous yeast Rhodosporidium toruloides
2018
Control of stem cell self-renewal and differentiation by the heterochronic genes and the cellular asymmetry machinery in Caenorhabditis elegans
2015 StandoutNobel
Sensitivity to First-Line Chemotherapy for Metastatic Breast Cancer in BRCA1 and BRCA2 Mutation Carriers
2009
Cancer Genome Landscapes
2013 StandoutScience
Hypoxia-inducible factor 1-dependent expression of platelet-derived growth factor B promotes lymphatic metastasis of hypoxic breast cancer cells
2012 StandoutNobel
PTEN Deficiency in Endometrioid Endometrial Adenocarcinomas Predicts Sensitivity to PARP Inhibitors
2010
Use and Abuse of RNAi to Study Mammalian Gene Function
2012 StandoutScienceNobel
CRISPR-Cas guides the future of genetic engineering
2018 StandoutScienceNobel
Photopharmacology: Beyond Proof of Principle
2014 StandoutNobel
E3 ubiquitin ligase Mindbomb 1 facilitates nuclear delivery of adenovirus genomes
2020 StandoutNobel
Works of Rachel Brough being referenced
Genome-wide Profiling of Genetic Synthetic Lethality Identifies CDK12 as a Novel Determinant of PARP1/2 Inhibitor Sensitivity
2013
Modeling Therapy Resistance in BRCA1/2 -Mutant Cancers
2017
ATR inhibitors as a synthetic lethal therapy for tumours deficient in ARID1A
2016
Cross-platform pathway-based analysis identifies markers of response to the PARP inhibitor olaparib
2012
The CST Complex Mediates End Protection at Double-Strand Breaks and Promotes PARP Inhibitor Sensitivity in BRCA1-Deficient Cells
2018
CDK1 Is a Synthetic Lethal Target for KRAS Mutant Tumours
2016
A synthetic lethal siRNA screen identifying genes mediating sensitivity to a PARP inhibitor
2008
Genome-wide barcoded transposon screen for cancer drug sensitivity in haploid mouse embryonic stem cells
2017
Resistance to therapy caused by intragenic deletion in BRCA2
2008 Nature
A Genetic Screen Using the PiggyBac Transposon in Haploid Cells Identifies Parp1 as a Mediator of Olaparib Toxicity
2013
Searching for synthetic lethality in cancer
2011
Synthetic lethal targeting of PTEN mutant cells with PARP inhibitors
2009
Synthetic lethality of PARP and NAMPT inhibition in triple‐negative breast cancer cells
2012